COMP Assay Kit
- Known as:
- COMP Assay Kit
- Catalog number:
- bp-003
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Kamiya biomedical company
- Gene target:
- COMP Assay Kit
Related genes to: COMP Assay Kit
- Gene:
- COMP NIH gene
- Name:
- cartilage oligomeric matrix protein
- Previous symbol:
- PSACH, EDM1, EPD1
- Synonyms:
- MED, THBS5
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-24
- Date modifiied:
- 2016-10-05
Related products to: COMP Assay Kit
Human ELC ELISA KIT 96 TEST
OxiSelect Hydroxyl Radical Antioxidant Capacity (HORAC) Activity Assay, Trial Size
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: COMP Assay Kit
- The smallest insects are particularly useful for studying how body size affects flight mechanics, because they include the smallest flying animals and operate at single-digit Reynolds numbers, where viscous forces play a much greater role than in larger insects and other flying animals. This area has attracted researchers for several decades, but until recently all work on "miniature" insects focused on species that are many times larger than the smallest insects. Recent work on some of the smallest insects has revealed the uniqueness of both the structure of their wing apparatus and the kinematics and aerodynamics of their flight. This review summarizes recent advances in the study of miniature insect flight and identifies unresolved questions that will shape future research in biology, biomechanics. and bioinspired technologies, providing broad prospects for a comprehensive study of this subject. - Source: PubMed
Publication date: 2026/08/12
Polilov A ALapina N APetrov P NKolomenskiy DShcherbakov E OFarisenkov S E - Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can lead to increased morbidity and mortality. This study described real-world treatment patterns and clinical outcomes by line of treatment among patients with PBC in the US. Adults (≥18 years) diagnosed with PBC on or after 1 January 17 were identified in the IQVIA PharMetrics Plus database and grouped into newly diagnosed, first-line (1L) and second-line or more (2L+) cohorts. Index date was initial PBC diagnosis or initiation of 1L or 2L therapy; follow-up continued until the earliest of end of continuous enrollment, death or data end. Time to treatment initiation, treatment discontinuation and negative clinical outcomes were assessed with Kaplan-Meier analysis. The newly diagnosed, 1L and 2L+ cohorts included 1748, 1659 and 181 patients, respectively (average age at index: 52.7-54.5 years; female: 84.2-89.0%). Of the newly diagnosed cohort, 34.8% did not initiate PBC treatment within 1.5 years post-diagnosis. In the 1L cohort, median time from diagnosis to 1L initiation was 1.2 months; median time from 1L initiation to 1L discontinuation/2L initiation was nearly 5 years. In the 2L+ cohort, median time from 2L initiation to 2L discontinuation was approximately 4 years. In the untreated, 1L, and 2L+ cohorts, 18.9%, 14.4% and 19.3% of patients developed ≥1 negative clinical outcome post-index (usually cirrhosis). Results of this US population-based study demonstrate a potential unmet need for early intervention and effective treatment options for patients with PBC, as one in three patients with PBC remain untreated years after diagnosis. - Source: PubMed
Publication date: 2026/08/12
Shamseddine NisreenYang HongboZhang SuYe DongniSeshasayee ShravanthiChen JingyiKumar SonalKowdley Kris V - Primary biliary cholangitis (PBC) is a rare liver disease associated with high morbidity. This study assessed the burden of fatigue and/or pruritus among patients with PBC in the US. This retrospective study used IQVIA PharMetrics Plus data (2016-2022). Patients with PBC and fatigue and/or pruritus were selected as cases. Controls were patients with PBC (no fatigue nor pruritus), matched 1:1 to cases by key characteristics. The index date for cases was a random symptom diagnosis date post-initial PBC diagnosis and for controls, a random medical visit date matching the time distribution from initial PBC diagnosis to index. Cumulative incidence of PBC comorbidities was described using Kaplan-Meier analysis and compared via Cox Proportional hazard models. Generalized estimating equations compared healthcare resource use (HRU) and costs per-patient-per-year. A total of 1839 fatigue cases/controls (mean age [years]: 56.5; 88.7% female) and 760 pruritus cases/controls were included (mean age [years]: 55.8; 90.8% female). Comorbidities at 1, 3 and 5-years post-index were higher for cases than controls (fatigue: 1.7 vs 0.7, 2.2 vs 0.9 and 2.5 vs 1.0; pruritus: 1.9 vs 0.8, 2.3 vs 1.0 and 2.7 vs 1.0; all p < 0.001). Common comorbidities were anxiety, urinary tract infection, depression and sleep disorders (hazard ratios in cases vs controls: fatigue, 1.3-4.0; pruritus, 1.5-2.8; all p < 0.01). One-year post-index, cases had higher rates of healthcare visits (incidence rate ratios: fatigue, 1.8-5.8; pruritus 1.6-6.1) and total healthcare costs (mean cost difference: fatigue, $42,515; pruritus $40,536). Patients with PBC who experience fatigue and/or pruritus faced a greater clinical and economic burden compared with those without these symptoms, highlighting the need for effective treatments to alleviate PBC symptoms. - Source: PubMed
Publication date: 2026/08/12
Kumar SonalShamseddine NisreenYang HongboZhang SuChen JingyiKowdley Kris V - Fruquintinib (Fruq), a selective VEGFR 1/2/3 inhibitor, showed a significant progression-free survival (PFS) benefit in the Phase III FRUTIGA trial for advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Ramucirumab (RAM), an anti-VEGFR2 antibody, demonstrated efficacy in the RAINBOW-Asia trial. This anchored matching-adjusted indirect comparison (MAIC) evaluated Fruq plus paclitaxel versus RAM plus paclitaxel as second-line therapy for G/GEJ adenocarcinoma in the absence of head-to-head trials. Data from individual patients in the FRUTIGA study (N = 703) and aggregated data from the RAINBOW-Asia study (N = 440) were analyzed. Baseline characteristics were balanced using entropy balancing. The placebo plus paclitaxel (PBO + PTX) groups served as the common comparators. The primary outcome was PFS; secondary outcomes included overall survival, objective response rate (ORR) and disease control rate (DCR). Rates of treatment-emergent adverse events (TEAEs) were also compared as an exploratory outcome using an adjusted indirect risk difference. Sensitivity analyses included restricted mean survival time and simulated treatment comparison. After weighting (effective sample size = 564), baseline covariates were balanced. The anchored MAIC demonstrated that Fruq + PTX significantly improved PFS compared with RAM + PTX (HR: 0.70; 95% CI: 0.51-0.96; p = 0.0280), corresponding to a 30% reduction in progression risk, with a significant restricted mean survival time benefit of 1.18 months at 20 months (95% CI: 0.08-2.27; p = 0.024). Fruq achieved significantly higher ORR (OR: 1.76, 95% CI: 1.16-2.68; p = 0.008) and DCR (OR: 1.94, 95% CI: 1.33-2.83; p < 0.001). Overall survival was similar (0.97; 95% CI: 0.73-1.30; p = 0.8640). Subgroup analyses showed PFS benefits with Fruq in patients with ECOG PS 1, peritoneal metastases and two or fewer metastatic sites. In sensitivity analysis, the simulated treatment comparison also suggested a PFS benefit for Fruq + PTX (HR: 0.40, 95% CI: 0.32-0.50; p < 0.0001). For any-grade TEAEs, the indirect comparison showed higher adjusted relative incidences of increased bilirubin with Fruq + PTX than with RAM + PTX (RD: 12.3%; 95% CI: 2.3-22.4%, p < 0.05) and of hypokalemia (RD: 9.0%; 95% CI: 1.5-16.4%, p < 0.05). For grade ≥3 TEAEs, the adjusted relative incidence of decreased body weight was higher with Fruq + PTX than with RAM + PTX (RD: 2.9%; 95% CI: 0.6-5.2%, p < 0.05). The adjusted relative incidences of increased AST, ALT and hypocalcemia were numerically lower in the fruquintinib group than in the RAM group. This MAIC indicates that Fruq + PTX may be more effective than RAM + PTX in second-line advanced G/GEJ adenocarcinoma, with potentially improved PFS, ORR and DCR, and similar overall survival. Safety analyses suggested generally comparable safety profiles across the two regimens. Fruq + PTX remains a valuable treatment option, offering important comparative evidence for clinical and health technology assessment decisions. Clinicaltrials.gov identifiers: NCT07144995. - Source: PubMed
Publication date: 2026/08/12
An NanChen JiayingLi JibinShen LinGuo WeijianLiu TianshuLi JinQin ShukuiBai YuxianChen ZhendongWang JufengPan YueyinXu RuihuaWang Feng - Anatomic location is a known prognostic factor for canine mast cell tumours (MCTs). Previous publications have reported conflicting results about the clinical significance of MCT location in the inguinal and perineal regions and male genitalia. Hence, the goal of this study is to evaluate the grade, breed distribution and clinical outcome of canine perivulvar MCT. Surgical biopsy reports and associated medical records submitted between 2013 and 2024 to Michigan State University Veterinary Diagnostic Laboratory were retrospectively evaluated. Information regarding age, reproductive status, breed, tumour location, microscopic description, histopathologic grade, and survival was collected. Kaplan-Meier analysis was used to estimate median survival time (MST) with dogs lost to follow-up (LTF) or alive censored from analysis. Biopsy reports from 64 dogs with 68 perivulvar MCT were evaluated. The most common phylogenetic classification was Mastiff-Terrier (47%). The majority (97%) of evaluated MCT were cutaneous, with 85% categorised as Kiupel low grade, while the remaining 15% were high grade. Three of 19 tumours (16%) that had c-KIT PCR performed had mutations in either Exon 8 or Exon 11. KIT expression pattern was classified as Pattern 2 or 3 in 71% of evaluated tumours. Median Ki-67 proliferation index and Ki-67 × AgNOR scores were 7 and 13, respectively. MST for the entire population was 868 days. Dogs LTF had a median follow-up time of 442 days. Dogs with perivulvar MCT may achieve prolonged survival time with surgical excision, and prospective studies are warranted to determine the effect of adjuvant therapy on outcome. - Source: PubMed
Publication date: 2026/08/12
Ahrens Madison RCorner Sarah MMasyr Alison